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The infl   ammatory bowel diseases (ulcerative 
colitis [UC] and Crohn’s disease [CD]) are 
chronic immune-mediated conditions that af-
fect more than one million patients in North 
America and lead to more than $3.6 billion in 
productivity losses each year (1, 2). The in-
fl  ammatory process is characterized by heavy 
leukocytic infi  ltration of the intestinal lamina 
propria (LP), leading to fi   brosis and loss of 
function (3, 4). Although the etiology of the 
disease remains mostly unknown, modulation 
of the immune response by immunomodu-
lators (e.g., azathioprine, 6-mercaptopurine), 
corticosteroids, and mAbs to TNF-α improve 
disease symptoms and outcomes (3–6). Al-
though UC aff  ects strictly the large intestine, 
CD primarily involves the small intestine, pre-
dominantly the terminal ileum (chronic ileitis) 
(3, 4). Thus, the recirculating lymphocyte pool 
likely possesses a defi  ned repertoire of adhesion 
molecules and chemokines (“address code”) 
(7) that allows them to distinguish between the 
small and large intestine. However, the specifi  c 
combination of molecules engaged by patho-
genic cells to localize specifi  cally to the small 
intestine has not been identifi  ed.
The recent characterization of mouse mod-
els that spontaneously develops chronic ileitis 
(i.e., the SAMP1/Yit and SAMP1/YitFc mod-
els) enabled us to study the traffi   cking pathways 
into the chronically infl  amed small intestine (8–
10). SAMP1/YitFc mice develop discontinu-
ous, transmural chronic infl  ammation localized 
to the small intestine (8, 9) that closely reca-
pitulates the human disease (10, 11). The LP is 
intensely infi  ltrated by eff  ector T cells, which 
display an activated phenotype and adoptively 
transfer disease to SCID mice (9). However, 
unlike the CD45RBhigh transfer model (12), 
lymphocytes from SAMP1/YitFc mice pre-
dominantly induce ileitis and not colitis, 
suggesting an inherent capacity to recirculate 
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L-selectin ligands might be relevant for infl  ammatory cell traffi  cking into the small intes-
tine in a spontaneous model of chronic ileitis (i.e., SAMP1/YitFc mice). Immunoblockade 
of peripheral node addressin or mucosal addressin cell adhesion molecule 1 failed to ame-
liorate ileitis, whereas P-selectin glycoprotein ligand 1 (PSGL-1) neutralization attenuated 
both the adoptively transferred and spontaneous disease. PSGL-1 was detected in venules 
of mesenteric lymph node and small intestine by immunohistochemistry and confi  rmed by 
real-time reverse transcription polymerase chain reaction and fl  ow cytometry. In addition, 
reconstitution of wild-type mice with PSGL-1−/− bone marrow demonstrated that PSGL-1 
messenger RNA and PSGL-1 protein expression remained on endothelium, localized within 
mesenteric lymph node and small intestine. Endothelial PSGL-1 bound P-selectin–IgG and 
its blockade or genetic deletion altered the recruitment of lymphocytes to the small in-
testine, as revealed by intravital microscopy and homing studies. Endothelial expression of 
PSGL-1 adds a new dimension to the various cellular interactions involved in small intesti-
nal recruitment. Thus, the multiple roles of PSGL-1 may explain why targeting this single 
adhesion molecule results in attenuation of chronic murine ileitis, a disease previously 
resistant to antiadhesion molecule strategies.
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preferentially to the small intestine (9). The resulting ileitis is 
also resistant to modulation by regulatory cells as cotransfer 
of CD45Rblow or CD25+ T cells, which abolishes colitis and 
has no eff  ect on ileitis (13). In addition, although colitis re-
sponds to single adhesion molecule blockade (14–17), ileitis 
requires interference with two or more adhesion pathways 
(i.e., ICAM-1/VCAM-1, L-selectin/mucosal addressin cell 
adhesion molecule-1 [MAdCAM-1], α4 integrins) (18, 19). 
This is in keeping with clinical trials in which patients with 
CD receiving natalizumab (a mAb that targets the shared α4 
moiety of both α4β7 and α4β1 integrins) achieved a clinical 
response, whereas specifi  c blockade of the gut-homing integ-
rin α4β7 was not more effi   cacious than the placebo (20–22).
Gut-homing CD4+ T cells from SAMP1/YitFc mice co-
express not only α4β7 and α4β1 integrins, but also L-selectin 
(19). This L-selectinhi population produces copious amounts 
of TNF-α and plays an important role in disease induction in 
SCID mice (19). L-selectin is involved in traffi   cking of naive 
and subpopulations of memory CD4+ T cells to intestinal 
sites (19, 23, 24), but the small intestinal endothelial L-se-
lectin ligands are not known. Identifi  cation of endothelial 
ligands that may be preferentially used in infl  ammatory traf-
fi  cking may prove valuable for the development of therapeu-
tic agents, as L-selectin is ubiquitously expressed.
Specialized endothelial cells express glycoproteins that 
serve as L-selectin ligands in secondary lymphoid organs, 
including a heterogeneous group of glycans that share the 
peripheral node addressin (PNAd) epitope (25, 26). MAd-
CAM-1 (the endothelial ligand for α4β7 integrin) is present 
in intestinal- and gastrointestinal-associated lymphoid tissues 
(27) and can also serve as an L-selectin ligand when appro-
priately glycosylated (28). P-selectin glycoprotein ligand 1 
(PSGL-1) (29) can also bind L-selectin (expressed on most 
leukocytes), P-selectin (expressed on infl  amed  endothelial 
cells and activated platelets), and E-selectin (expressed on in-
fl  amed endothelial cells) (30, 31).
The potential role of L-selectin in traffi   cking to the in-
fl  amed small intestine prompted us to search for its associ-
ated intestinal endothelial ligands. A monoclonal antibody 
against PSGL-1, but not any other single antiadhesion mol-
ecule strategy, attenuated both the CD4+-induced and the 
spontaneous ileitis. Unexpectedly, not only the infi  ltrating 
leukocytes, but also endothelial cells from small intestine and 
mesenteric lymph node (MLN) expressed functional PSGL-1.
Our results, therefore, suggest that PSGL-1 is an integral part 
of the address code for small intestinal homing and that it 
is critically involved in recruitment of leukocytes, includ-
ing   eff  ector CD4+ T cells, into the LP of the chronically 
  infl  amed small intestine.
RESULTS
PSGL-1 plays a critical role in chronic murine ileitis
We have recently shown that L-selectin plays an important 
role in adoptively transferred chronic ileitis (19), a disease in-
duced by pathogenic CD4+ T cells (9). To identify relevant 
L-selectin ligands within the microcirculation of the terminal 
ileum, we designed a series of therapeutic studies. SCID mice 
adoptively transferred with CD4+ T cells isolated from donor 
SAMP1/YitFc mice develop severe ileitis within 6 wk (9, 18).
The PNAd epitope (shared by several L-selectin ligands) 
was expressed within the MLN of infl  amed SCID mice, but 
not in those from their noninfl  amed counterparts (Fig. 1 A). 
Therefore, 6 wk after adoptive transfer, we targeted PNAd 
using the mAb MECA-79 alone (not depicted) or in combi-
nation with anti–MAdCAM-1 (MECA-367) for 3 d (Fig. 1 B) 
to determine whether PNAd was the critical small intestinal 
endothelial ligand. This treatment provided no therapeutic 
benefi  t (active index = 4.5 ± 0.7, chronic index = 4.4 ± 0.9) 
compared with mice treated with isotype antibodies (active
index = 4.1 ± 0.6, chronic index = 4.9 ± 0.6).
MAdCAM-1 serves as a ligand for α4β7 integrin and for 
L-selectin when appropriately glycosylated (27, 28). The mAb 
MECA-367 interferes with α4β7 binding, whereas MECA-89 
blocks interactions with L-selectin (32). However, MAdCAM-1
Figure 1.  Peripheral node adressin (PNAd) expression and blockade 
in adoptively transferred ileitis. (A) Immunohistochemistry was per-
formed on frozen sections before (left) and 6 wk after transfer (right) as 
per the description in Materials and methods. PNAd expression was de-
tected in MLN HEVs (right) of SCID mice with chronic ileitis, but not 
before adoptive transfer (left). Representative micrographs from tissues 
obtained from three mice before and after transfer are shown. Bars, 100 μm. 
(B and C) The effect of antibody blockade on infl  ammatory indices. 
(B) Infl  amed SCID mice were treated with isotype mAb (n = 12), with 
anti-PNAd/anti–MAdCAM-1 antibodies combined (MECA-79 + MECA 
367, n = 10) or (C) with isotype mAb (n = 8), with anti–MAdCAM-1/anti–
PSGL-1 antibodies combined (4RA10 + MECA 367, n = 7), or with anti–
PSGL-1 antibody (4RA10, n = 7). Error bars show the mean ± SEM from 
four independent experiments.JEM VOL. 203, April 17, 2006  909
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does not appear to be the critical small intestinal endothelial 
ligand, as there was no therapeutic benefi  t after MECA-89 anti-
body treatment alone or when combined with MECA-367 
(active index = 4.8 ± 0.7, chronic index = 5.7 ± 0.7) com-
pared with isotype-treated controls (active index = 5.3 ± 0.8, 
chronic index = 5.2 ± 0.9) (unpublished data).
We tested whether PSGL-1, a known pan-selectin li-
gand, could be the endothelial counterpart responsible for the 
therapeutic eff  ect of L-selectin blockade. Using the function-
blocking mAb 4RA10 (33), we targeted PSGL-1 alone or 
combined with anti–MAdCAM-1 mAb MECA-367 in in-
fl  amed SCID mice. Animals were administered three doses 
of mAb/s every other day, 6 wk after adoptive transfer, as the 
ileitis reached maximum severity. 4RA10 reduced both ac-
tive and chronic infl  ammatory indices (active index = 3.4 ±
0.4, chronic index = 3.8 ± 0.5) compared with isotype-
treated controls (active index = 5.6 ± 0.3, chronic index =
5.5 ± 0.4, P < 0.01) (Fig. 1 C). Additional MAdCAM-1 
blockade did not signifi  cantly improve the eff  ect (4RA10/
MECA 367; active index = 2.8 ± 0.4, chronic index = 2.7 ±
0.6; the p-value vs. 4RA10 was not signifi  cant).
PSGL-1 blockade attenuated spontaneous chronic ileitis
To investigate whether a similar therapeutic eff  ect could be 
achieved on the spontaneous ileitis of SAMP1/YitFc mice, 
we administered three doses of the 4RA10 mAb (200 μg) 
every other day to 10-wk-old mice, which at that age exhibit 
robust ileitis. Prior studies had shown that, at this time point, 
the disease is refractory to all antiadhesion strategies evaluated 
(18). However, 4RA10 reduced the villous distortion index 
by 30% (P < 0.005) (Fig. 2 A), the active infl  ammatory index 
(granulocytic infi  ltrates) by 70% (P < 0.0001) (Fig. 2 B), and 
the chronic infl  ammatory index (lymphocytic/monocytic in-
fi  ltrates) by 50% (P < 0.0005) (Fig. 2 C) compared with 
isotype-treated controls (Fig. 2, black bars). The total infl  am-
matory index was reduced by 50% (P < 0.0001) (Fig. 2 D) 
and restoration of the villous and crypt architectures was also 
observed in the 4RA10-treated mice (Fig. 2, E and F). No 
other single or combined antiadhesion molecule strategy has 
shown comparable therapeutic benefi  t (18). The therapeutic 
eff  ect of anti–PSGL-1 mAb in SAMP1/Yit mice has been 
independently verifi  ed by Inoue et al. (34).
PSGL-1 expression increased on activated effector CD4+ 
T cells from SAMP1/YitFc mice
To identify potential cellular targets for PSGL-1 immuno-
blockade, we investigated whether expression of PSGL-1 or 
its reactivity to P-selectin were aff  ected by the chronic in-
fl  ammatory process. Flow cytometric analyses of MLN cells 
demonstrated a signifi  cantly higher percentage of activated 
CD44high cells in SAMP1/YitFc mice compared with nonin-
fl  amed AKR mice (P < 0.01) (Fig. 3 A), whereas essentially 
all MLN CD4+ T cells from both strains expressed PSGL-1. 
In contrast, although only 1.3% of uninfl  amed AKR CD4+/
CD44high MLN cells bound P-selectin–IgG, this fraction in-
creased to 7% in infl  amed SAMP1/YitFc mice (P < 0.001) 
(Fig. 3 B), consistent with regulation of PSGL-1 function at 
the posttranslational level. The majority of the P-selectin–
binding CD4+ T cells were found within the CD44high-
activated population. The addition of 5 mM EDTA abolished 
selectin binding in both strains (unpublished data).
Leukocyte PSGL-1 is not required for the development 
of ileitis
Prior studies suggested that monocyte-expressed PSGL-1 
was the critical element in the attenuation of ileitis achieved 
by anti–PSGL-1 treatment in SAMP1/Yit mice (34). To 
ascertain whether leukocyte PSGL-1 was required for the 
development of ileitis, we generated bone marrow chimeric 
SAMP1.B6MHC mice reconstituted with PSGL-1–suffi   cient 
(C57BL/6J, WTBM) or PSGL-1–defi  cient bone marrow. In 
this SAMP1 congenic substrain, the MHC originates from 
C57/BL/6J mice, allowing bone marrow transplantation 
from PSGL-1−/− mice on C57/BL6/J background. The 
mixed genetic background of native SAMP1/YitFc mice 
precludes such manipulation as the result of MHC mismatch. 
Heterozygous and homozygous Chr 17 congenics did not 
Figure 2.  Anti–PSGL-1 antibody attenuates ileitis in SAMP1/YitFc 
mice. (A–D) Mice were injected with isotype mAb (black bars, n = 12) or 
with and anti–PSGL-1 antibody (4RA10) (white bars, n = 10), ileal tissues 
were harvested, and infl  ammatory indices were determined as described 
in Materials and methods. Error bars show the mean ± SEM from two 
independent experiments. (E and F) The effect of indicated treatment on 
intestinal architecture (representative micrographs, hematoxylin and 
eosin). Bars, 150 and 200 μm, respectively.910  ROLE OF PSGL-1 IN CHRONIC MURINE ILEITIS | Rivera-Nieves et al.
diff  er from the parental SAMP1/YitFc strain in their cumu-
lative incidence, kinetics, or severity of ileitis (median total 
ileitis score: SAMP = 9.8, SAMP.B6-MHC = 10.5; n = 13 
and 24, respectively); therefore, neither the MHC nor other 
loci on Chr 17 regulate disease susceptibility (35). The disease 
of SAMP1.B6MHC mice reconstituted with PSGL-1–defi  -
cient bone marrow was indistinguishable from that of mice 
reconstituted with PSGL-1–suffi   cient bone marrow, suggest-
ing that leukocyte-expressed PSGL-1 was not required for 
the development of ileitis.
Levels of soluble P- and E-selectins increased in infl  amed 
SAMP1/YitFc mice, but pan-selectin antagonism did not 
attenuate chronic ileitis
Pan-selectin antagonism through targeted blockade of PSGL-1 
(a pan-selectin ligand) is an obvious potential mechanism for 
the therapeutic eff  ect of 4RA10. Therefore, we fi  rst   examined 
whether P- and E-selectins played a role in the   development 
of ileitis by measuring the levels of soluble selectins in se-
rum as the disease progressed from 4 to 28 wk. Both soluble 
P- and E-selectin levels increased from 4 to 8 wk during 
the early stages of the disease and reached a plateau thereafter 
(Fig. 4 A). This correlation between soluble serum selec-
tin levels and severity of infl  ammation supported a role for 
both P- and E-selectins in the development of the disease 
and   justifi  ed a therapeutic study in which all selectins were 
simultaneously targeted. However, targeting all three selec-
tins in 10-wk-old SAMP1/YitFc mice off  ered no therapeutic 
benefi  t (Fig. 4 B), suggesting that pan-selectin antagonism 
was not the sole mechanism of the disease-attenuating eff  ect 
of mAb 4RA10.
Small intestinal endothelial cells express PSGL-1
We conducted immunohistochemical studies to determine 
whether the frequency of PSGL-1–expressing leukocytes 
increased with the infl  ammatory infi  ltrates of the chronically 
infl  amed small intestine. Unexpectedly, PSGL-1 immuno-
reactivity was not only observed on hematopoietic cells 
but also on microvessels within the small intestinal villi and 
submucosa of infl   amed adoptively transferred SCID mice 
(AT SCID, Fig. 5), as well as in terminal ileal microvessels 
of SAMP1/YitFc mice with chronic ileitis (Fig. 5). Because 
many of these vessels were located within infl  amed sites, we 
conducted additional experiments to determine whether in-
fl  ammation was required. PSGL-1 expression was similarly 
found on microvessels of noninfl  amed AKR mice, which do 
not develop ileitis, (Fig. 5) but not in PSGL-1–defi  cient mice 
or in mice that received an isotype-matched nonspecifi  c anti-
body, followed by a secondary antibody (anti–rat horseradish 
peroxidase [HRP] conjugate). To exclude leukocyte frag-
ment-derived PSGL-1 (36) as the source for the endothelial 
Figure 3.  A higher percentage of SAMP1/YitFc (SAMP) CD4+/
CD44high MLN cells bind P-selectin–IgG compared with cells from 
uninfl  amed AKR control mice (AKR). (A) PSGL-1 expression and (B) P-
sel–IgG binding to MLN cells were analyzed by fl  ow cytometry and gated 
on forward light scatter (FSC), side light scatter (SSC), and CD4. Represen-
tative data obtained from four and three mice, respectively. (C) The sever-
ity of ileitis was determined in SAMP1.B6MHC mice reconstituted with 
PSGL-1–suffi  cient (WT) or defi  cient (PSGL−/−) bone marrow. Error bars 
show the mean ± SEM.
Figure 4.  Soluble serum P- and E-selectin levels were elevated in 
infl  amed SAMP1/YitFc mice but pan-selectin antagonism is not 
solely responsible for the effect of PSGL-1 immunoblockade. (A) The 
severity of ileitis (left) and the serum levels of soluble P- and E-selectins 
(middle and right) were determined in SAMP1/YitFc mice as the disease 
progressed (mean ± SEM, n = 5 mice/time point). (B) SAMP1/YitFc mice 
at 10 wk of age received antibodies against P-, E-, and L-selectins (mAb 
RB40.34, 9A9, MEL-14) or their respective isotype antibodies combined 
and the severity of the ileitis was assessed as described. Error bars show 
the mean ± SEM; n = 7 mice/treatment group.JEM VOL. 203, April 17, 2006  911
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signal, we tested mice that lack P-, E-, and L-selectins (37). 
Leukocytes from these mice are expected to show little or no 
leukocyte rolling, limiting leukocyte-derived PSGL-1 depo-
sition. However, P-, E-, L-selectin–defi  cient mice similarly 
showed robust endothelial PSGL-1 expression (Fig. 5).
Endothelial PSGL-1 binds P-selectin
To confi  rm endothelial PSGL-1 expression and function at 
the single cell level, we obtained ileal LP mononuclear cells 
by collagenase digestion, followed by a 2-h incubation at 37°C 
and staining of the adherent population for CD31, a pan-
  endothelial cell marker. Leukocytes were further depleted 
magnetically, removing cells that expressed CD45, a pan-leuko-
cyte marker (Fig. 6 A) (38). 34% of the CD45neg/CD31pos cells 
expressed PSGL-1 (Fig. 6 B), consistent with PSGL-1 expres-
sion in venules, which account for approximately one third 
of all microvascular endothelial cells. The same percentage of 
ileal endothelial cells was able to bind P-selectin–IgG (Fig. 
6 C), but not a control human IgG chimera (not depicted), 
demonstrating that the endothelium-expressed PSGL-1 was 
functional. To directly demonstrate the expression of PSGL-1
message by endothelial cells, mRNA was extracted from a 
cellular fraction magnetically depleted of CD45+ cells (98% 
CD45neg), followed by further purifi  cation CD45neg/CD31pos 
small intestinal endothelial cells using FACS sorting. The 
presence of PSGL-1 mRNA was subsequently confi  rmed by 
real-time RT-PCR (unpublished data).
PSGL-1 mRNA expression localized to the small intestine 
and MLN of PSGL-1−/−→WT bone marrow chimeric mice
To quantitatively measure PSGL-1 mRNA in situ and to 
determine whether PSGL-1 expression localized to specifi  c 
tissues, we generated bone marrow chimeric mice through 
reconstitution of lethally irradiated wild-type C57BL/6J mice 
with bone marrow progenitors from PSGL-1−/− mice (31). 
PSGL-1−/−→WT chimeric mice lacked leukocyte-derived 
PSGL-1(Fig. 7 A), but continued to express PSGL-1 within 
small intestinal endothelium (Fig. 7 B). Real-time RT-PCR 
of PSGL-1−/−→WT chimeric mice tissues localized PSGL-1 
mRNA within the duodenum, jejunum, ileum, and MLN 
but not within the kidney, spleen, liver, bone marrow, or 
heart. Peripheral blood leukocytes from control mice recon-
stituted with wild-type bone marrow (WT→WT) expressed 
PSGL-1 on leukocytes (Fig. 7 A), as well as PSGL-1 mRNA 
in all organs surveyed, commensurate with their leukocyte 
Figure 5.  Small intestinal endothelial cells express PSGL-1. Immuno-
histochemistry was performed on frozen terminal ileal sections from the 
indicated mouse strains as per Materials and methods. PSGL-1 expression 
was detected on leukocytes and in venules within the LP and submucosa 
of adoptively transferred SCID mice (AT SCID), SAMP1/YitFc, and AKR 
mice. Minimal or no expression was observed in PSGL-1–defi  cient (−/−) 
mice or in AKR ileum reacted with anti–rat HRP after isotype antibody 
injection (Anti–rat HRP), whereas robust expression was seen in P-, E-, 
L-selectin triple-defi  cient (−/−) mice, which lack rolling leukocytes. Bar, 
200 μm. Inset, high power of SAMP1/YitFc submucosal venules. Bar, 20 μm.
Figure 6.  Primary intestinal endothelial cell PSGL-1 expression 
and reactivity with P-sel-IgG chimera. (A). LP mononuclear cells were 
obtained from terminal ilea of SAMP1/YitFc mice and plated for 2 h at 
37°C. Adherent cells were recovered and stained for three color fl  ow 
cytometry as per Materials and methods. Cells were gated on FSC, SSC, 
 CD45neg, CD31+. (B) PSGL-1 expression was determined within the CD-
45neg, CD31+ gated cells (unshaded histogram) and compared with cells 
stained with isotype mAb control (shaded histogram). (C) Reactivity with 
P-sel–IgG chimera was determined in CD45neg, CD31+ gated cells. Repre-
sentative data from four (A and B) and two (C) independent experiments, 
respectively, are shown.912  ROLE OF PSGL-1 IN CHRONIC MURINE ILEITIS | Rivera-Nieves et al.
content (Fig. 7 C, black bars). PSGL-1−/− tissues, used 
as negative control, lacked PSGL-1 mRNA (representative 
PSGL-1−/− MLN shown, Fig. 7 C). Collectively, these data 
demonstrate that venular endothelial cells in the small intes-
tine and MLN express functional PSGL-1.
Functional signifi  cance of endothelial PSGL-1 
for lymphocyte recruitment
To examine the in vivo signifi  cance of endothelial PSGL-1
expression in the recruitment process to the small intestine, 
we performed homing assays and intravital microscopy. 
CD4+/L-selectin+ lymphocytes were enriched magnetically, 
radioactively labeled with chromium 51 and adoptively trans-
ferred into PSGL-1–suffi   cient (+/+) and –defi  cient (−/−) 
mice. To account for the possibility that chronic infl  amma-
tion may be required for the posttranslational modifi  cations 
that render endothelial PSGL-1 functional for small intesti-
nal recruitment, we used PSGL-1–defi  cient and –suffi   cient 
TNF∆ARE mice that, like SAMP1/YitFc mice, develop 
chronic ileitis (39). Decreased incorporation of radioactivity 
was observed throughout the small intestine and colon of 
PSGL-1–defi  cient TNF∆ARE mice; however, these diff  er-
ences reached statistical signifi  cance only in the MLN and 
ileum (P < 0.05). No diff  erences in recruitment were seen 
in the liver, kidney, or colon (Fig. 8).
Prior immunohistochemical studies have shown that the 
PSGL-1 signal was not exclusively present in villous and 
submucosal microvessels, but that some larger caliber ves-
sels within the muscularis and serosa also expressed PSGL-1 
(Fig. 9 A, arrow). Using intravital microscopy, we identi-
fi  ed serosal venules of the terminal ileum in which rolling of 
fl  uorescently labeled cells could be visualized before and after 
injection of an anti–PSGL-1 mAb (4RA10). To exclude the 
possibility that a potential eff  ect of the anti–PSGL-1 mAb 
could be mediated by interference with leukocyte PSGL-1, 
the injected cells originated from PSGL-1–defi  cient mice. 
Most of the observed rolling occurred in serosal vessels of 
 50–80 μm in diameter, where engaged cells (Fig. 9 B, red 
arrows) could be identifi  ed as they advanced much slower 
than their free-fl  owing counterparts (Fig. 9 B, blue arrow-
heads). A signifi  cant reduction in the number of rolling cells 
( 70%) was observed after anti–PSGL-1 antibody injection 
(Fig. 9 C). As the rolling cells lacked PSGL-1, the eff  ect of
the antibody must be attributed to interference with endo-
thelial PSGL-1 interactions.
D  I  S  C  U  S  S  I  O  N 
L-selectin ligands are expressed at sites of chronic infl  amma-
tion, including the small intestine of patients with CD (26), 
but their role in recruitment of L-selectin–expressing leuko-
cytes directly into eff  ector sites is incompletely understood 
(26). In this study, we demonstrate that the pan-selectin 
ligand PSGL-1 plays a critical role in ileitis, as the function-
blocking antibody (4RA10) decreased granulocytic and 
lymphocytic infi  ltrates in both CD4+-dependent and spon-
taneous murine ileitis. Moreover, we demonstrate that small 
intestinal high endothelial venule (HEV)-like vessels express 
functional PSGL-1. Its immunoblockade results in decreased 
rolling leukocytes, decreased recruitment of CD4+ T cells to 
the terminal ileum, and attenuated ileitis. Our results provide 
evidence that PSGL-1 is part of the address code for small 
intestinal traffi   cking.
Figure 7.  Endothelial PSGL-1 expression localized to the small intes-
tine and MLN of PSGL1−/− → WT bone marrow chimeric mice. (A) Peri-
pheral blood leukocytes from PSGL-1–defi  cient or indicated bone marrow 
chimeric mice were incubated with PE anti–PSGL-1 (2PH1) antibody as per 
Materials and methods. Cells were gated on FSC, SSC, and CD3. (B) Endothelial 
PSGL-1 was detected by immunohistochemistry in mice reconstituted with 
PSGL-1–defi  cient bone marrow using mAb 4RA10. Bar, 150 μm. (C) PSGL-1 
mRNA levels from indicated organs of bone marrow chimeric and PSGL1−/− 
mice. Indicated tissues were harvested, RNA was obtained, and real-time RT-
PCR was performed as per Materials and methods. Representative histograms, 
tissues, and mRNA expression were obtained from at least four bone marrow 
chimeric mice per group and run in triplicate. Error bars show the mean ± SEM.JEM VOL. 203, April 17, 2006  913
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The mAb MECA-79 recognizes several sialomucins 
(PNAd) that, when properly glycosylated, serve as L-selectin 
ligands. Functionally, MECA-79 blocks lymphocyte interac-
tions with HEVs in vitro and short-term lymphocyte homing 
to lymph nodes in vivo (25). Its role in infl  ammatory traf-
fi  cking has been shown in the infl  amed pancreas (40, 41) and 
lacrimal glands (42). MECA-79 binds to HEV-like vessels 
in the organized lymphoid aggregates present in chronically 
infl  amed tissues (26). Although we demonstrate PNAd ex-
pression in SCID mice with ileitis, no benefi  cial therapeutic 
eff  ect was seen by MECA-79 administration.
MAdCAM-1, the α4β7 integrin endothelial ligand ex-
pressed in intestine and gastrointestinal-associated lymphoid 
tissues (27), serves as an L-selectin ligand when appropriately 
glycosylated (7, 27, 28). MAdCAM-1 is constitutively ex-
pressed in postcapillary venules of intestinal LP, MLN, and 
Peyer’s patches HEVs (27, 43), and is aberrantly expressed in 
the infl  amed pancreas (39). Furthermore, MAdCAM-1 is up-
regulated in the chronically infl  amed small and large intestine 
of patients with UC and CD, where it is likely induced by 
TNF-α (43, 44). The mAb MECA-367 binds to the fi  rst Ig 
domain of MAdCAM-1 and interferes with α4β7 binding, 
whereas MECA-89 binds to the second Ig domain, which in-
terferes with L-selectin interactions as a result of its proximity 
to the mucinous portion of MAdCAM-1 (32). If MAdCAM-1
mediated critical L-selectin interactions in the gut, we would 
expect that combined MECA-367/MECA-89 treatment 
would provide the same benefi  t as combined MECA-367/
MEL-14 (19). However, administering MECA-89 together 
with MECA-367 provided no added therapeutic benefi  t.
PSGL-1 binds to L-selectin (29), E-selectin, and P-selec-
tin (30, 31). The most comprehensive survey of PSGL-1 ex-
pression to date identifi  ed bone marrow–derived cells as the 
primary site of expression, whereas expression by endothelial 
cells was limited to small venules and capillaries of pathologi-
cal tissues (i.e., benign prostatic hypertrophy and fi  brocystic 
disease of the breast) (45). PSGL-1 binding to selectins is reg-
ulated by fucosyltransferases, core 2-glucosaminyltransferases, 
sialyltransferases, and sulfotransferases, which are constitu-
tively expressed in myeloid cells but regulated in lymphocytes. 
Figure 8.  Homing of CD4+ T cells to the terminal ileum is impaired 
in PSGL-1–defi  cient mice. Chromium 51–labeled L-selectin+ CD4 T cells 
were injected into PSGL-1–suffi  cient (+/+) and –defi  cient (−/−) 
TNF∆ARE mice as per Materials and methods. Radioactivity was deter-
mined in the aforementioned organs 72 h after cell transfer. Error bars 
show the mean ± SEM from three mice/experimental group. *, P < 0.05.
Figure 9.  PSGL-1 blockade decreased splenocyte–endothelial 
interactions in the small intestinal vasculature. (A) Endothelial PSGL-1 
signal was observed in small (arrowhead) and large vessels (yellow arrow) 
within the small intestinal muscularis and serosa. The larger serosal ves-
sels were monitored via intravital microscopy. Bar, 200 μm. (B) Rolling 
CFSE-labeled PSGL-1–deficient cells (red arrows) proceed much 
slower than cells not interacting with wild-type vessels (blue arrowhead) 
before (B) PSGL-1 blockade. (C) A signifi  cant decrease in the number of 
rolling cells was observed after injection of 4RA10 (percent of normalized 
total rolling cells [error bars show the mean ± SD] before and after 
4RA10 injection from four experiments in which one to three vessels/
mouse were monitored; *, P < 0.05).914  ROLE OF PSGL-1 IN CHRONIC MURINE ILEITIS | Rivera-Nieves et al.
Thus, eff  ector memory cells of the Th1 type bind selectins 
better than Th2 polarized CD4+ T cells (30, 46–48). Endo-
thelial cells also express most, if not all, of these glycosyltrans-
ferases (49), suggesting that all of the machinery necessary to 
express functional selectin binding activity is present.
Diff  erent from other models of colitis that may be suc-
cessfully treated by blockade of single adhesion molecules 
(14–17), the spontaneous chronic ileitis of SAMP/Yit mice is 
refractory to single and to many combined antiadhesion mol-
ecule strategies (i.e., MAdCAM-1, α4β7 integrin, ICAM-1, 
VCAM-1, α4 integrin, combined ICAM-1/VCAM-1, and 
ICAM-1/α4) (18). In contrast, the current data shows that 
targeting PSGL-1 alone ameliorates ileitis. This eff  ect cannot 
be solely explained by the expected pan-selectin antagonism 
as combined blockade of all three selectins failed to attenuate 
ileitis. Expression of PSGL-1 on ileal endothelium provides 
a plausible explanation of why blockade of a single adhe-
sion molecule is eff  ective. First, PSGL-1 blockade prevents 
entry of functional PSGL-1–expressing (Th1-polarized) (30, 
46–48) and L-selectin–expressing (naive and subpopulations 
of memory CD4+ T cells) into MLN and ileal LP (19, 23), 
where endothelial PSGL-1 acts as an “addressin” for small in-
testinal homing of L-selectin–expressing cells. Second, anti–
PSGL-1 interferes with recruitment of PSGL-1+ granulocytes 
and monocytes, as well as those expressing L-selectin, which 
might use endothelial PSGL-1 as a ligand. Third, blocking 
PSGL-1 prevents secondary leukocyte tethering to P-selec-
tin on adherent platelets, as well as PSGL-1/P-selectin- 
and/or PSGL-1/L-selectin–mediated leukocyte–leukocyte 
and leukocyte–platelet interactions. P-selectin–PSGL-1 
interactions are known to exacerbate atherosclerosis (50) 
and dextran sulfate sodium–induced colitis (51). Ligation of 
PSGL-1 on activated Th1 cells may also induce rapid apopto-
sis of these cells, which are known to be pivotal for induction 
and maintenance of ileitis (52).
Collectively, our data demonstrate that PSGL-1 is consti-
tutively expressed on endothelial cells of the MLN and small 
intestine. In this location, endothelial PSGL-1 may act as an 
addressin to support homing of L-selectin–expressing leuko-
cytes and memory T cells into the small intestinal LP and 
MLN. Because the SAMP1/YitFc model shares many fea-
tures of the human disease, it would be reasonable to expect 
that PSGL-1 may represent a viable therapeutic target for the 
treatment of patients with CD.
MATERIALS AND METHODS
Mice. SAMP1/YitFc mice were generated by brother–sister matings for 
>30 generations from two breeding pairs provided by S. Matsumoto (Yakult 
Institute for Microbiological Research, Tokyo, Japan) and kept under spe-
cifi  c pathogen-free conditions at the University of Virginia (9, 10). As most 
identifi  able genes were AKR derived, age-matched AKR/J mice were used 
as controls (35). Fecal samples from SAMP1/YitFc mice were consistently 
negative for Helicobacter hepaticus, Helicobacter bilis, and other mouse Helico-
bacter species, as well as for protozoa and helminthes.
C3SnSmn.CB17-Prkdcscid/J SCID mice (6–8 wk old) (The Jackson 
Laboratory) were purchased and housed at the University of Virginia vi-
varium under specifi  c pathogen-free conditions for 1 wk before SAMP1/
YitFc CD4+ T cell adoptive transfer and thereafter. PSGL-1−/− and E-, P-, 
L-selectin–defi  cient mice, both on C57BL/6 background were generated as 
described previously (31, 37).
TNF∆ARE mice were generated as described previously (39), backcrossed 
to C57BL/6J mice (18 generations), and kept under specifi  c pathogen-free 
conditions. The C57BL/6J genetic background did not alter the localiza-
tion, time course, or severity the intestinal infl  ammation (unpublished data). 
TNF∆ARE+/−/PSGL-1−/− were generated by crossing TNF∆ARE+/− 
mice to PSGL-1−/− mice. The double mutant mice were obtained after two 
backcrosses. PSGL-1 defi  ciency was confi  rmed by PCR and fl  ow cytometry 
of peripheral leukocytes.
SAMP.B6-MHC congenic mice for alleles from the C57BL/6J (B6) 
chromosome 17 were generated by introgression of a B6 interval defi  ned by 
the microsatellite loci D17Mit16 (31.3 Mb) and D17Mit221 (87.9 Mb) onto 
the SAMP genetic background using a marker-assisted selection (“speed 
congenic”) protocol. This interval included the entire major histocompat-
ibility complex, converting the new congenic strain to the H-2b haplotype 
from H-2k. This change renders SAMP.B6-MHC congenic mice as suit-
able recipients for bone marrow from C57BL/6J (B6) mice and PSGL-1−/− 
mice on this background, without altering the intestinal phenotype (35). All 
animal handling procedures were approved by the University of Virginia 
Health Sciences Center institutional committee for animal use.
Tissue collection and histological analyses. Mice were anesthetized 
and killed at the times required by the experimental design. The MLN was 
identifi  ed at the confl  uence of the mesenteric vasculature and harvested. The 
distal ilea (10 cm) were resected, opened, rinsed of debris, oriented from dis-
tal to proximal, and pinned longitudinally in corkboard. Tissues were fi  xed 
in 10% buff  ered formalin or Bouin’s, embedded in paraffi   n, and cut into 3–5 
μm sections. Resulting sections were stained with hematoxylin and eosin. 
Histological assessment of ileal infl  ammation was performed by a single pa-
thologist in a blinded fashion using a standardized semi-quantitative scoring 
system as described previously (18).
Immunohistochemistry. Mice were injected with mAbs 4RA-10 against 
PSGL-1, MECA-79 against PNAd or isotype control mAb (IgG1, IgM, re-
spectively) i.p. MLN and ilea were harvested 30 min after mAb injection and 
snap frozen, and sections (5 μm) were cut on a cryostat (Microm HM505N). 
Secondary staining was conducted with rabbit anti–rat antibody HRP using 
either VIP purple or DAB as substrates and methyl green or hematoxylin as 
counterstains, respectively (Vector Laboratories). Nonspecifi  c binding was 
reduced using normal mouse serum (Sigma-Aldrich). Tissues from mice 
  injected with isotype antibody served as controls.
Determination of serum soluble P- and E-selectin levels. Serum lev-
els of soluble P- and E-selectins were determined by ELISA per the manu-
facturer’s instructions from mice of the indicated ages (R&D Systems).
Intestinal LP lymphocyte and endothelial cell isolation. MLN were 
aseptically removed at the time of necropsy. Single cell suspensions were 
obtained by gently pressing the MLN against a 100-μm cell strainer. LP 
mononuclear cell isolation was performed as described previously (19).
Cell culture. For enrichment of adherent endothelial cells, LP mononuclear 
cells were cultured at 37°C in six-well fl  at-bottom plates at 106 cells/ml in 
complete medium (RPMI 1640 with 10% FBS, 2 mM L-glutamine and 1% 
penicillin/streptomycin) for 2 h or leukocytes were depleted using CD45+ 
magnetic beads.
T cell and endothelial cell enrichment and separation. Enriched 
CD4+ T cell fractions were obtained by incubation with anti-CD4–bound 
magnetic beads and sorted into discrete populations, using a magnetic cell–
sorting system. Endothelial cell fractions were enriched by depleting the LP 
mononuclear cell fraction of CD45+ cells using anti-CD45 magnetic beads 
(Miltenyi Biotec) following manufacturer’s instructions. Flow cytometry 
confi  rmed 95–97% purity of CD4+ T cell fractions and 98% purity of CD45 
negative fraction, which was further purifi  ed by FACS sorting.JEM VOL. 203, April 17, 2006  915
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CD4+ T cell adoptive transfer. SAMP1/YitFc (30–40 wk old) mice 
MLN were harvested and rendered into a single cell suspension, followed by 
positive selection for CD4 using magnetic beads. CD4+ lymphocytes (105/
mouse) were injected i.p. or i.v. into 6–8-wk-old SCID mice (The Jackson 
Laboratory). Neither the selection protocols (positive or negative) nor the 
route of injection (i.p. or i.v.) altered the severity or time course of disease. 
Mice were housed in a barrier facility and fed irradiated, standard chow. After 
5 wk, the adoptively transferred mice showed ileitis with moderate to severe 
LP leukocyte infi  ltration and architectural changes (villous and crypt distor-
tion, goblet cell hyperplasia, and hypertrophy of the muscularis propia).
In vivo homing. The in vivo migration of lymphocytes was analyzed as 
described previously (53). In brief, magnetically enriched CD4+/CD62L+ 
lymphocytes were labeled with 20 μCi chromium 51/ml. A total of 50 × 
106 lymphocytes suspended in 0.5 ml were injected i.p. into 8–12-wk-old 
C57BL/6J (n = 3) or PSGL-1−/− mice (n = 3). Mice were killed after 72 h 
and the distribution of radioactivity in diff  erent organs was measured. Each 
sample was counted to 3% statistical error. The mean values and their stan-
dard error were determined from three animals per strain.
Flow cytometry and cell sorting. Fluorescently tagged monoclonal an-
tibodies reactive with PSGL-1 (PE-labeled 2PH1; BD Biosciences) or P-sel 
human Ig-G chimera (2 μg/106 cells; BD Biosciences) or control CD4-
human IgG chimera (2 μg/106 cells, a gift from J.B. Lowe, University of 
Michigan, Ann Arbor, MI) preincubated with allophycocyanin-labeled 
anti–human IgG Fab fragments (Zenon Human IgG labeling kit; Invitrogen) 
were subsequently incubated with cells in suspension for 20 min, includ-
ing FITC-labeled anti-CD4 (GK1.5) for gating of MLN cells or PERCP 
anti-CD45 (30-F11) and FITC or allophycocyanin–anti-CD31 (390) (BD 
Biosciences) for gating of intestinal endothelial cells. Cells were fi  xed with 
1% paraformaldehyde and three-to-four color analyses were performed using 
the FACS Calibur system (Becton Dickinson Immunocytometry Systems). 
Further analyses were performed using FLOWJo software (Tree Star Inc.). 
Endothelial cells were sorted using a FACSVantage sorter.
Real-time RT PCR. RT-PCR primers and Taqman probes were designed 
using Beacon Designer V3.0 software (Premier Biosoft). The primers were 
designed to amplify WT PSGL-1 mRNA but not mRNA from PSGL-1−/− 
mice (truncated protein). Total RNA was isolated using RNAeasy Mini-
Kit (QIAGEN) with DNase treatment (Rnase-Free Dnase Kit; QIAGEN). 
Reverse transcription was performed using 500 ng of RNA with an Om-
niscript RT Kit (QIAGEN) and oligo-dT primers. The primers were tested 
for specifi  city by standard PCR using cDNA made from WT mice and 
PSGL-1−/− mice. Reaction conditions were optimized and 2 μL of sample 
cDNA was multiplexed with GAPDH and PSGL-1 primers on an iCycler 
iQ Real-Time Detection System (QIAGEN). Values were determined using 
the iCycler iQ Real-Time Detection System Software v3.0a (QIAGEN). 
The corresponding values were normalized to GAPDH. The PSGL-1 prim-
ers used were: forward 5′-C  T  T  C  C  T  T  G  T  G  C  T  G  C  T  G  A  C  C  A  T  -3′, reverse 
5′-T  C  A  G  G  G  T  C  C  T  C  A  A  A  A  T  C  G  T  C  A  T  C  -3′ and probe 5′-C  C  A  A  C  C  A  C-
C  T  G  C  C   T  C  C  G  T  T  C  C  C  G  -3′.
Therapeutic interventions. mAbs (200 μg each) against the following: 
PNAd (MECA-79, IgM), PSGL-1 (4RA-10, IgG1), MAdCAM-1 (MECA-
367 or MECA 89, rat IgG 2a), P-selectin (RB40-34, IgG1), E-selectin 
(10E9.6, IgG2A), L-selectin (MEL-14, IgG2a), or irrelevant corresponding 
isotype control mAb were injected i.p. every other day for 3 d, 5 wk after 
adoptive transfer of SCID mice or at 10 wk of age for SAMP1/YitFc mice. 
Mice were killed 16–18 h after the last dose. MECA-367, MECA 79, and 
MECA-89 were obtained from the American Type Culture Collection. 
4RA10 was obtained from D. Vestweber (University of Munster, Munster, 
Germany). Antibodies were produced and purifi  ed by HPLC from hybrid-
oma supernatants at the University of Virginia Biomolecular Core Facility.
Generation of bone marrow chimeric mice. C57BL/6J bone marrow 
transplant recipients were irradiated twice with 600 rad before and 4–6 h after 
injection of donor cells. Bone marrow cells were harvested in RPMI 1640 
containing 10% fetal calf serum. 7.5 × 106 cells/500 μl were injected into the 
tail veins of recipient mice. Mice were killed 6–10 wk after transplantation.
Intravital microscopy. C57BL/6J mice were prepared for intravital mi-
croscopy as per previously described methods (54). A 1.5-cm incision was 
made along the linea alba and the cecum and terminal ileum were exposed. 
The intestinal serosa was covered with plastic wrap and superfused with 
bicarbonate-buff   ered saline containing 100 nM isoproterenol. CFSE-la-
beled cells (10–20 × 106/200 μl PBS) from PSGL-1−/− mice were injected 
through a jugular vein catheter and the serosal vessels in which rolling cells 
could be visualized by stroboscopic epifl  uorescence microscopy were se-
lected for monitoring. All monitored vessels were 30–80 μm in diameter. 
Two to three vessels per mouse were selected and rolling cells were counted 
before and after antibody injection. The number of rolling cells before 
4RA10 was normalized to 100% and the percent reduction after 4RA10 
treatment was calculated.
Statistics. Statistical analyses for fl  ow cytometry and infl  ammatory indices 
were performed using the two-tailed unpaired Student’s t test. Data were 
expressed as mean and standard error of the mean. Statistical signifi  cance was 
set at P < 0.05.
Online supplemental material. Supplemental Videos 1 and 2 depict the 
interactions between CFSE-labeled PSGL-1−/− cells and intestinal endothe-
lium before and after injection of mAb 4RA10; they are available at http:// 
www.jem.org/cgi/content/full/jem.20052530/DC1.
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